Press Review (August 11, 2012) – Revue de presse (11 août 2012)

Komen Foundation Leaders Step Down Amid Turbulent Year for Organization‎‎

The founder and president join exodus from leading breast cancer nonprofit following controversy.

By Seth Cline. In U.S. News & World Report

http://www.usnews.com/news/articles/2012/08/09/komen-foundation-leaders-step-down-amid-turbulent-year-for-organization

Amgen pancreatic cancer drug lacks efficacy, trial ends

Amgen Inc halted a late-stage trial of an experimental drug for pancreatic cancer after independent reviewers concluded that it was unlikely to significantly help patients.

Amgen said the trial of ganitumab, also known as AMG479, did not raise any safety concerns. The company said it would also stop a separate mid-stage trial of the drug.

In Chicago Tribune

http://www.chicagotribune.com/health/sns-rt-us-amgenbre8771g9-20120808,0,1054216.story

How Chemotherapy May Trigger Tumors' Resistance‎‎‎

The researchers, from Fred Hutchinson Cancer Research Center, characterized the protein as an unfriendly “neighbor” that lives in the same environment as cancer cells.

By Alexandra Sifferlin. In TIME

http://healthland.time.com/2012/08/07/how-chemotherapy-may-trigger-tumors-resistance/

Prostate Cancer Among African American Men Reaches 'Epidemic' Proportions, Senate Says‎‎ ‎‎

Despite ongoing debate about the benefits of PSA testing for men at risk for prostate cancer, and recent research on the best course of treatment for those who have been diagnosed, the U.S. Senate passed a resolution Thursday acknowledging that awareness and prevention of the disease is as critical as it's ever been for African American men.

In Huffington Post

http://www.huffingtonpost.com/2012/08/03/prostate-cancer-african-american-men-epidemic-senate-says_n_1738391.html

Zaltrap: Colon Cancer Drug Approved By FDA‎

The U.S. Food and Drug Administration said on Friday that it had approved the Sanofi SA and Regeneron Pharmaceuticals Inc drug Zaltrap for patients with metastatic colorectal cancer whose tumors have failed to respond to earlier treatment with chemotherapy.

By Ransdell Pierson. In Huffington Post

http://www.huffingtonpost.com/2012/08/07/zaltrap-colon-cancer-drug-fda-approved_n_1753114.html

Cancer : de prochains traitements issus de la mer‎

Certaines bactéries, éponges et micro-algues marines renferment des molécules jamais observées auparavant et potentiellement utilisables en chimiothérapie.

Par Anne Jeanblanc. Dans Le Point

http://www.lepoint.fr/chroniqueurs-du-point/anne-jeanblanc/cancer-de-prochains-traitements-issus-de-la-mer-07-08-2012-1493644_57.php

Cancer : la chimiothérapie pourrait être contre-productive‎‎

Une étude publiée dans la revue Nature Medicine pourrait changer l'idée que l'on se fait de la chimiothérapie. Les chercheurs du Fred Hutchinson Cancer Research Center de Seattle auraient en effet découvert que celle-ci abîmerait des cellules saines, déclenchant chez elles la production d'une protéine alimentant les tumeurs.

Dans MaxiSciences

http://www.maxisciences.com/cancer/cancer-la-chimiotherapie-pourrait-etre-contre-productive_art26069.html

La femme qui dit non à la Légion d'honneur de Cécile Duflot‎‎ ‎‎

Annie Thébaud-Mony, directrice de recherche honoraire à l’Inserm, figurait sur la liste des trente promus sélectionnés par Cécile Duflot, la ministre du Logement. Elle lui a écrit hier pour refuser sa Légion d’honneur.Un geste destiné à attirer l’attention sur « l’impunité qui, jusqu’à ce jour, protège les responsables de crimes industriels ».

Dans Rue89

http://www.rue89.com/2012/08/05/la-femme-qui-dit-non-la-legion-dhonneur-de-cecile-duflot-234403

LEAD 1-Sanofi/Zaltrap-Feu vert de la FDA dans le cancer colorectal

Sanofi et son partenaire américain Regeneron ont annoncé vendredi avoir obtenu un feu vert de l'autorité sanitaire américaine (FDA) pour commercialiser le Zaltrap dans le traitement du cancer colorectal métastatique

Dans Reuters

http://fr.reuters.com/article/frEuroRpt/idFRL6E8J3P0P20120803